Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sancilio Pharmaceuticals Co. Inc.

www.sancilio.com

Latest From Sancilio Pharmaceuticals Co. Inc.

Pipeline Watch: Phase III Progress With Keytruda, Bempedoic Acid And Ubrogepant

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Pipeline Watch

Pipeline Watch: Patisiran, Etrolizumab, ALKS8700 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With Rimegepant, ARQ087 And SGX942

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Emmaus Plans Modest Pricing In 4Q Rollout Of Sickle Cell Drug Endari

With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.

Approvals Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Gastrointestinal
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sancilio Pharmaceuticals Co. Inc.
  • Senior Management
  • Frederick Sancilio, Chmn., Pres. & CEO
    Mark Wolff, EVP & CFO
    Adrian L Rabinowicz, MD, CMO
  • Contact Info
  • Sancilio Pharmaceuticals Co. Inc.
    Phone: (561) 847-2302
    2129 N Congress Avenue
    Riveria Beach, FL
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register